Tempo Therapeutics: Revolutionizing Regenerative Medicine with $12 Million Funding
March 21, 2024, 9:34 pm
Tempo Therapeutics
Location: United States, California, San Diego
Employees: 11-50
Founded date: 2014
Total raised: $12M
Tempo Therapeutics, a pioneer in tissue engineering and regenerative medicine, has secured a significant milestone with the completion of a $12 million Series A funding round. Led by Galaxy-Sirius Partners and Johnson & Johnson Innovation – JJDC, Inc., this funding will propel Tempo forward in advancing its groundbreaking Microporous-Annealed-Particle (MAP) technology platform.
With this infusion of capital, Tempo is set to embark on the first-ever clinical trials of surgical scaffolds based on MAP technology. As the exclusive developer of MAP technology-based tissue scaffolds, Tempo is on track to achieve crucial development goals by validating the safety and efficacy of its lead products: TT101 and TT108.
TT101 is designed for complex surgical sites with exposed bone, tendon, or fascia, while TT108 focuses on reinforcing fascial incision sites. These innovative products hold the potential to transform medical outcomes by promoting the growth of healthy, native tissue instead of scar tissue.
The MAP technology utilized by Tempo represents a paradigm shift in regenerative medicine. By leveraging a volumetric injectable porous scaffolding approach, Tempo can facilitate tissue ingrowth and integration without triggering the typical inflammatory response associated with foreign body implants. This regenerative immune response leads to the accelerated formation of vascularized tissue volume, setting a new standard in tissue engineering.
Westbrook Weaver, the visionary Founder and CEO of Tempo Therapeutics, expressed gratitude for the confidence shown by investors in the company's mission. He emphasized the commitment to innovation and excellence that drives Tempo towards redefining the possibilities in regenerative medicine.
As Tempo prepares to enter human clinical testing, the potential impact of its technology across a wide range of surgical procedures and therapeutic areas is immense. The clinical data generated from these trials will be instrumental in moving Tempo closer to commercializing a revolutionary product that could revolutionize patient outcomes on a global scale.
In a landscape where medical technology is constantly evolving, Tempo Therapeutics stands out as a beacon of innovation and promise. With the support of strategic investors and a dedicated team, Tempo is poised to make a lasting impact in the field of regenerative medicine, paving the way for a future where tissue engineering transforms the way we approach healthcare.
With this infusion of capital, Tempo is set to embark on the first-ever clinical trials of surgical scaffolds based on MAP technology. As the exclusive developer of MAP technology-based tissue scaffolds, Tempo is on track to achieve crucial development goals by validating the safety and efficacy of its lead products: TT101 and TT108.
TT101 is designed for complex surgical sites with exposed bone, tendon, or fascia, while TT108 focuses on reinforcing fascial incision sites. These innovative products hold the potential to transform medical outcomes by promoting the growth of healthy, native tissue instead of scar tissue.
The MAP technology utilized by Tempo represents a paradigm shift in regenerative medicine. By leveraging a volumetric injectable porous scaffolding approach, Tempo can facilitate tissue ingrowth and integration without triggering the typical inflammatory response associated with foreign body implants. This regenerative immune response leads to the accelerated formation of vascularized tissue volume, setting a new standard in tissue engineering.
Westbrook Weaver, the visionary Founder and CEO of Tempo Therapeutics, expressed gratitude for the confidence shown by investors in the company's mission. He emphasized the commitment to innovation and excellence that drives Tempo towards redefining the possibilities in regenerative medicine.
As Tempo prepares to enter human clinical testing, the potential impact of its technology across a wide range of surgical procedures and therapeutic areas is immense. The clinical data generated from these trials will be instrumental in moving Tempo closer to commercializing a revolutionary product that could revolutionize patient outcomes on a global scale.
In a landscape where medical technology is constantly evolving, Tempo Therapeutics stands out as a beacon of innovation and promise. With the support of strategic investors and a dedicated team, Tempo is poised to make a lasting impact in the field of regenerative medicine, paving the way for a future where tissue engineering transforms the way we approach healthcare.